Because of the possible interplay between TOPK and other molecular targets known to be involved in leukemia such as ERK1/2, CDK1, and CyclinB1, we hypothesized that TOPK might play some role in AML and therefore may serve as a therapeutic target in this disease. This evidence concerns the gene MAPK3 and acute myeloid leukemia.